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BACKGROUND: Evidence-based guidelines recommend limited perioperative diagnostic imaging for new breast cancer diagnoses.
For patients aged >65 years, conventional imaging use (mammography, plain radiographs, and ultrasound) has remained stable,
whereas advanced imaging (computed tomography [CT], nuclear medicine scans [positron emission tomography/bone scans], and
magnetic resonance imaging [MRI]) use has increased. In this study, the authors evaluated traditional and advanced imaging use
among younger patients (aged 65 years) undergoing breast cancer surgery. METHODS: The MarketScan Commercial Claims and
Encounters Research Database from 2005 through 2008 was analyzed to evaluate the use of conventional and advanced diagnostic
imaging associated with surgery for ductal carcinoma in situ (DCIS) or stage I through III invasive breast cancer. RESULTS: The study
cohort included 52,202 women (13% with DCIS and 87% with stage I-III breast cancer). The proportion of patients undergoing con-
ventional imaging remained stable, whereas the average number of conventional imaging tests per patient increased from 4.21 tests
in 2005 to 4.79 tests per patient in 2008 (P<.0001). For advanced imaging, the proportion of women who underwent imaging
increased from 48.8% in 2005 to 68.8% in 2008 (P<.0001), as did the number of tests per patient (from 1.53 tests in 2005 to 1.98
tests in 2008; P< .0001). MRI examinations accounted for nearly all of the increase in advanced imaging. Patients who underwent MRI
examinations received significantly more traditional imaging tests compared with to those who did not, indicating that these tests
are additive and are not replacing traditional imaging. CONCLUSIONS: The current results demonstrate that the use of perioperative
breast MRI has increased among women aged <65 years. Further study is indicated to determine whether the benefits of this proce-
dure justify increased use. Cancer 2013;119:1251-6. VC 2012 American Cancer Society.
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INTRODUCTION
Cancer care accounts for a substantial and increasing component of medical expenditure in the United States.1
Breast cancer, the most commonly diagnosed malignancy among women in the United States, is associated with
high initial and ongoing costs compared with other tumor types, and the use of advanced medical technology is
a major contributing component to these costs.1,2 Data from the Surveillance, Epidemiology, and End Results
(SEER)/Medicare linked database demonstrate that, for patients aged >65 years, the use of conventional imag-
ing (mammography, plain radiographs, and ultrasound [US]) associated with a breast cancer diagnosis has
remained stable, whereas the use of advanced imaging, such as computed tomography (CT) scanning, positron
emission tomography (PET) scanning, and magnetic resonance imaging (MRI) has increased.3 Although this
research describes compelling trends in imaging use for older Americans with breast cancer, 50% of women
who receive treatment for breast cancer are aged <65 years at diagnosis. Population-level studies evaluating
diagnostic imaging use in younger population are lacking and further study is warranted, because these women
may have different preferences and patterns of use for diagnostic imaging.4-6
Clinical practice guidelines for breast cancer management recommend limited diagnostic imaging evaluation
in conjunction with initial therapy. The objective of traditional diagnostic imaging examinations is to estimate the
extent of disease and identify subclinical disease in the affected and contralateral breast to guide local therapy.
Advanced imaging technologies such as CT and PET scanning are used to detect metastatic disease, but they are
only recommended for patients with higher stage disease (stage IIIA and above).7 Breast imaging with MRI may
have utility in select situations, such as screening high-risk populations in which a highly sensitive test may be de-
sirable,8 but its use for surgical planning in early stage breast cancer is controversial due to its high false-positive
rate.6,9 To understand patterns of diagnostic imaging use in younger women with breast cancer, we evaluated the
use of traditional and advanced imaging for women undergoing breast cancer surgery in a commercial insurance
database over a 4-year period.
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We used the MarketScan Commercial Claims and
Encounters Research Database for the years 2005 through
2008. Medstat compiles this database from claims sub-
mitted to health plans that contract with large private
employers, public agencies, and public organizations in
the United States. Health plan types that are included in
this database are employer-sponsored, private, fee-for
service, and capitated insurance to employees and covered
dependents. This longitudinal database tracks all patient-
level inpatient and outpatient claims for as long as the
employees remain with their employers.
The study cohort included women ages 18 to 63
years with continuous enrollment in a participating
health plan for at least 3 months before and 3 months af-
ter the initial diagnosis or surgery date who underwent
mastectomy or breast-conserving surgery and had 2
encounters associated with invasive breast cancer (Inter-
national Classification of Diseases, ninth revision [ICD-
9] code 174.x) or ductal carcinoma in situ (ICD-9 code
233.0) separated by 30 days. To avoid counting more
than 1 episode of care per patient, we analyzed only the
first breast cancer-associated episode of care during the
study period.10 To ensure the most complete data on
each patient, women who were aged 64 years at the
time of initial diagnosis were excluded, because their
claims would have been submitted to Medicare when
they reached age 65 years, and data from supplemental
insurance plans may be incomplete. We also excluded
patients who had stage IV breast cancer (ICD-9 codes
197.x, 198.x, and 199.x), because these patients have
different indications for imaging compared with patients
who have earlier stage breast cancer.
For each individual in the cohort, we extracted data
on age, health plan type, stage (DCIS vs stage I-III breast
cancer), and claims for breast surgical procedures. Tumor
stage was assigned in the following manner: We assumed
that patients with invasive breast cancer (ICD-9 code
174.x) without an accompanying code for DCIS (ICD-9
code 233.0) or stage IV breast cancer (ICD-9 codes
197.x, 198.x, 199.x) had stage I through III cancer.
Detailed staging information was not available in this
data set, so the analysis was performed on the aggregated
group. We defined an episode of care to include 3
months before and 3 months after the surgical procedure
to capture testing done during the diagnostic and initial
treatment phases. Diagnostic procedure codes were used
to identify the use of traditional imaging studies, includ-
ing mammography, plain radiographs, breast US, and
advanced imaging studies, including CT, MRI, and PET
scanning.
Statistical Analysis
Univariate tests were used to examine associations
between diagnostic testing used, patient age, surgical
treatment, and health plan type. Time-trend analysis was
used to assess changes in diagnostic testing use over time.
Logistic regression analysis was used to model the likeli-
hood of undergoing tests as a function of age, year, and
health plan type.
RESULTS
The initial cohort included 81,878 patients who under-
went breast-conserving or mastectomy procedures
TABLE 1. Study Cohort Characteristics
No. of Patients (%)
Characteristic Totals 2005 2006 2007 2008 P
Total 52,202 9876 11,798 14,237 16,291
Age (years)
18-29 267 53 (0.5) 60 (0.5) 67 (0.5) 87 (0.5) .9260
30-39 3435 656 (6.6) 780 (6.6) 927 (6.5) 1072 (6.5)
40-49 15,463 2891 (29.3) 3521 (29.8) 4218 (29.6) 4833 (29.6)
50-64 33,037 6276 (63.5) 7437 (63) 9025 (63.4) 10,299 (63.4)
Health plan type
Encounter 8222 1899 (19.2) 1677 (14.2) 2033 (14.3) 2613 (14.3) < .0001
FFS 43,980 7977 (80.8) 10,121 (85.8) 12,204 (85.7) 13,678 (85.7)
Disease stage
DCIS 6271 1031 (10.4) 1355 (11.5) 1721 (12.1) 2164 (12.1) < .0001
I-III 45,931 8845 (89.6) 10,443 (88.5) 12,516 (87.9) 14,127 (87.9)
Surgical therapy
Lumpectomy 33,504 6530 (66.1) 7778 (65.9) 9015 (63.3) 10,181 (63.3) < .0001
Mastectomy 18,698 3346 (33.9) 4020 (34.1) 5222 (36.7) 6110 (36.7)
Abbreviations: DCIS, ductal carcinoma in situ; FFS, fee for service.
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between 2005 and 2008. After excluding patients without
continuous enrollment for 3 months before and 3 months
after the surgery or initial diagnosis date (n¼ 20,908),
patients aged <18 years or >64 years at the time of sur-
gery (n¼ 288), those who had less than 2 claims associ-
ated with a breast cancer diagnosis 30 days apart
(n¼ 8181), men (n¼ 184), and patients with stage IV di-
agnosis codes or no diagnosis associated with their proce-
dure (n¼ 115), the final study cohort consisted of 52,202
patients. The number of breast cancer cases identified
each year increased, reflecting changes in enrollment by
participating plans. The age distribution in the cohort
remained stable, whereas enrollment in encounter-based
health plans (P< .001), the proportion of patients with
stage 0 diagnoses (P< .001), and the use of mastectomy
increased modestly (P< .001) (Table 1).
The number of tests per patient associated with a
breast cancer episode increased over time in both the con-
ventional and advanced imaging categories. The propor-
tion of women who received at least 1 conventional
imaging test was high throughout the study period
(97.1% in 2005 and 97.9% in 2008); however, the
average number of conventional imaging tests per patient
increased significantly from 4.21 tests per patient in 2005
to 4.79 tests per patient in 2008 (P< .0001). The average
number of traditional tests per patient was higher in
patients who underwent lumpectomy compared with
those who underwent mastectomy. Advanced imaging use
also increased in terms of both the proportion of patients
receiving tests and the number of tests per patient. In
2005, 48.8% of patients underwent at least 1 advanced
imaging test. By 2008, this proportion increased to
68.8% (P< .0001). Similar to traditional imaging, the av-
erage number of advanced imaging studies performed per
patient increased from 1.53 tests per patient to 1.98 tests
per patient in 2008 (P< .0001) (Fig. 1).
MRI examinations accounted for nearly all of the
increase in advanced imaging test use, whereas use of CT
and PET scanning declined slightly over the study period.
In 2005, 22.8% of patients underwent an MRI; by 2008,
this proportion increased to 52.9% (Fig. 1, top). Patients
who underwent MRI examinations received significantly
more traditional imaging tests compared with those who
did not (Fig. 2).
The increased use of advanced imaging—and specif-
ically MRI—was observed across all age groups, for both
health plan types, and for both DCIS and invasive cancer.
The odds of undergoing an MRI were greatest in the
youngest age group and for those who had fee-for-service
versus encounter-based health plan types, and they
increased in each year of the study. After adjustment for
age, health plan type, disease stage, and surgical proce-
dure, the odds of undergoing an MRI in 2008 were 3.81
times greater compared with 2005 (Table 2).
DISCUSSION
In this analysis of claims data from commercial insurance
companies, we have documented an increase in use of
Figure 1. (A) Proportion of patients who underwent
advanced imaging in each category. The Mantel-Haenzel chi-
square test significant for all test categories (P< .0001)
except computed tomography (CAT) scan (P¼ .0011); (B) The
average number of tests performed per patient in traditional
and advanced categories.
Figure 2. Average number of traditional tests per patient in
patients who did or did not undergo magnetic resonance
imaging (MRI).
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both traditional and advanced imaging tests associ-
ated with a diagnosis of breast cancer in women
aged 18 to 63, 2005 to 2008. Diagnostic testing
increased in both the conventional and advanced
imaging categories, indicating that advanced imaging
added to, but did not replace, less expensive tradi-
tional imaging in this cohort. Increased use of MRI
was responsible for the majority of the increase in
advanced imaging use. Although the overall propor-
tion of patients who underwent traditional imaging
remained stable, patients who underwent MRI
received significantly more traditional tests compared
with those who did not undergo MRI.
Our results are consistent with those of other investi-
gators documenting an increase in claims for advanced
imaging services in a variety of clinical settings.11-13 Sev-
eral prospective studies have reported increased tumor
detection in high-risk women who undergo MRI as part
of their breast cancer screening program.8,14 MRI is
highly sensitive and can identify clinically and mammo-
graphically undetectable lesions; for this reason, some in
the breast cancer treatment community advocate routine
MRI for treatment planning. In support of this concept,
single-institution, retrospective reports estimate changes
in surgical management for 1% to 28% of patients in
whom perioperative MRI is used for treatment planning
for invasive carcinoma.15 However, a recent multicenter,
prospective, randomized trial failed to demonstrate an
improvement in reoperation rates or health-related
quality of life in women who underwent preoperative
breast MRI.16 In addition, the excellent local control rates
that have been achieved using breast-conserving therapy
with clinical and mammographic assessment are well
established through multiple randomized clinical trials
predating the routine use of breast MRI.17
There is a lack of agreement in the breast cancer
treatment community regarding the precise role of MRI
in surgical planning for invasive breast cancer. The
National Comprehensive Cancer Network describes MRI
testing as an optional procedure for perioperative plan-
ning,7 whereas others support its use in specific clinical
situations.18 Still others recommend extreme caution
when using MRI for perioperative treatment planning for
invasive cancer.9 The MRI characteristics of DCIS also
have been explored, but there are no evidence-based
guidelines recommending the routine use ofMRI to guide
surgical excision.19 Other influences which may have con-
tributed to this increase in MRI use include the increased
availability of MRI scanners,20 patient demand, institu-
tional pressure to use expensive capital equipment, and
potential physician self-referral for diagnostic imaging
services.21
Our study has several limitations. First, the
MarketScan data set contains insurance billing data from
select employers, and the patterns of care we describe may
not be representative of the care delivered in other set-
tings. Second, administrative billing data do not provide
details regarding the specific indications for using various
testing procedures or whether or not actual treatment
decisions were changed based on test results. Some
patients who initially considered breast-conserving sur-
gery may have opted for mastectomy after MRI, and vice
versa, depending on test results, personal preference, or
physician input. We also did not have access to patient-
level data regarding potential benefits, such as reassurance
and diminished anxiety with a negative MRI result, or
potential harms, such as increased anxiety and additional
testing with a suspicious or positive MRI finding. Third,
this data set lacks specific staging information and follow-
up regarding local or distant recurrence, so it is impossible
to determine whether the patients who underwent MRI
benefited in terms of improved oncologic outcomes.
Finally, we did not have access to information regarding
whether or not the participating health plans reimbursed
for MRI services, so some out-of-pocket MRI use may
have been unmeasured.
We have documented a substantial increase in the
use of traditional and advanced imaging services
TABLE 2. Odds of Undergoing Magnetic
Resonance Imaging Adjusted for Age, Health Plan
Type, Stage, Surgical Therapy, and Year of Breast
Procedure
Patient Characteristic Adjusted OR (95% CI)
Age (years)
50-64
40-49 vs Ref 1.52 (1.46-1.59)
30-39 vs Ref 1.79 (1.66-1.92)
18-29 vs Ref 1.91 (1.48-2.45)
Health plan type
FFS vs Encounter 1.10 (1.05- 1.16)
Disease stage
I-III vs DCIS 1.22 (1.16-1.30)
Surgical therapy
Mastectomy vs lumpectomy 1.03 (0.99-1.07)
Year of breast surgery
2005
2006 vs Ref 1.39 (1.30-1.47)
2007 vs Ref 2.55 (2.41-2.70)
2008 vs Ref 3.81 (3.60-4.04)
Abbreviations: CI, confidence interval; DCIS, ductal carcinoma in situ; FFS,
fee for service; OR, odds ratio; Ref, referent category.
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associated with a breast cancer diagnosis in women aged
<65 years between 2005 and 2008. This important
patient population includes the primary target group for
mammographic screening, and >50% of incident breast
cancer cases occur in this age group.5,22 Although the pro-
portion of patients who received traditional imaging
remained stable, the number of traditional tests per
patient increased. For advanced imaging, both the pro-
portion of patients who underwent tests and the number
of tests per patient increased. In addition, patients who
underwent MRI received more traditional imaging than
those who did not, indicating that MRI did not replace
traditional imaging. It is possible that some of the addi-
tional traditional imaging tests were done to evaluate
abnormalities identified on MRI, indicating that there
may be downstream costs associated with MRI testing.
We observed an increase in the proportion of patients
who were diagnosed with DCIS, which is consistent with
national trends.2 The increase in use of mastectomy
(P< .0001) was statistically significant but numerically
small, and we were not able to determine whether this
trend reflected increased use of unilateral mastectomy or
contralateral risk-reducing mastectomy, as demonstrated
in the SEER/Medicare population.23
PerioperativeMRI is a procedure with uncertain ben-
efits and known monetary costs. The use of this test as well
as associated traditional imaging tests is increasing in
patients with breast cancer. In an effort to improve patient
care and reduce cost, professional organizations have rec-
ommended that patients and clinicians question the utility
of testing during initial cancer treatment and follow-up.24
Although perioperative MRI is not explicitly addressed in
these recommendations, clinicians should carefully con-
sider whether using advanced medical imaging at the time
of breast cancer diagnosis will provide additional value for
their patients or potentially may lead to unnecessary testing
and procedures. In addition, additional prospective studies
are needed to determine whether patients experience psy-
chological benefit or harm from undergoingMRI and asso-
ciated testing or have improved outcomes in terms of local
or distant disease control.
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